MGMT and neoplasm: In any case, irrespective of the underlying molecular mechanism, our finding that a single, clinically relevant cycle of TMZ/O6BG results in survivors with a consistent MSH6-deficient phenotype demonstrates the emergence of a secondary resistance mechanism beyond MGMT, and provides a reasonable explanation for why tumor cells might escape TMZ/O6BG treatment in the clinic.